AgomAb Therapeutics (NASDAQ:AGMB) Sets New 1-Year High – Here’s What Happened

AgomAb Therapeutics NV (NASDAQ:AGMB)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $17.45 and last traded at $15.99, with a volume of 19525 shares trading hands. The stock had previously closed at $16.21.

AgomAb Therapeutics News Roundup

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Major brokerages initiated or reiterated bullish coverage with high price targets that imply large upside vs. the current price — JPMorgan started coverage at “Overweight” with a $32 PT (~+118%). JPMorgan Coverage
• Positive Sentiment: Leerink Partners initiated coverage at “Outperform” with a $36 price target (~+145%), which could attract momentum buying from institutional investors. Leerink Coverage (Benzinga) Leerink Coverage (Zacks)
• Positive Sentiment: Morgan Stanley initiated coverage at “Overweight” with a $28 price target (~+91%), reinforcing analyst-driven upside expectations across the sell-side. Morgan Stanley Coverage
• Neutral Sentiment: Short-interest reports posted large increases in “short interest” for early March, but the published figures are internally inconsistent (showing 0 shares and NaN changes); the data appears unreliable and provides no clear signal on actual short pressure. Investors should treat these short-interest entries with caution until corrected filings are available.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Leerink Partners started coverage on AgomAb Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective for the company. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $28.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $32.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.00.

AgomAb Therapeutics Stock Performance

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.